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Abstract Large-sized gold nanoparticles, promising imaging
and therapeutic tools in human cancer, need long-term studies
evaluating tissue bio-distribution in blood, organs and tumor.
In a preclinical model of mouse xenografted with human renal
cancer, we analysed the bio-distribution of a single dose
(160 μg/kg) intravenously injected of poly-ethylene glycol
(PEG)ylated gold nanoshells (~150 nm), in blood, normal
and tumoral tissues. Using inductively coupled plasma mass
spectrometry (ICP-MS), dark field and electron microscopy,
we performed a sequential study of nanoshell uptake and
distribution in the tumor. We also studied microscopically
the organsmost sensitive to efficient anticancer drugs to detect
a possible long-term toxicity. Gold quantities significantly
decreased in blood between early and late time points,
whereas they significantly increased in liver and spleen. In
addition, gold nanoshells did not induce any tissue damage,
such as necrosis, inflammatory infiltrate or fibrosis in mouse
liver, spleen, kidney or bonemarrow after 6 months. In human
renal cancer xenografts, ICP-MS showed an early decrease of
gold, with 1-week stability before decrease at Day 15. Dark
field microscopy showed gold particles within the vessel
lumen 5 to 30 min after nanoshell injection, while 24 h later,
gold particle distribution was mainly intracellular. Electron
microscopy identified nanoshells within blood vessels at 5
and 30 min, within endothelial cells at 3 and 6 h and within
cytoplasms of macrophages in the tumoral tissue after 24 h. In
conclusion, no toxicity was observed in mice 6 months after
administration of PEGylated gold nanoshells and the
distribution kinetics progressed from intravascular flow at
30 min to intratumoral cells 24 h later.
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Introduction
Gold nanoparticles are now synthesised into a large variety of
forms. Only some of them are suitable for in vivo hyperthermia.
A recent comparative study of small-sized gold nanoparticles
including nanorods, nanocages and nanohexapods demonstrated
the value of nanohexapods for in vivo photothermal destruction
using 18F-fluorodesoxyglucose positron emission tomography/
computed tomography [1]. Large-sized gold nanoparticles (NPs)
such as nanoshells about 150 nm in diameter are also promising
tools for imaging and therapeutic approaches in cancer [2].
In preclinical models, the spherical particles of silica–gold
nanoshells have shown optical properties for imaging and
photothermal targeted therapy [3, 4]. In addition, a poly-
ethylene glycol (PEG) coating reduces the adsorption of blood
serum proteins to the nanoparticles [1]. Liu et al. [5] also
demonstrated that PEGylation is a key factor that governs
the fate of gold nanoparticles in the animal organisms and
their accumulation in target organs. PEGylated gold
nanoshells enter more easily into organs and tissues [6].
Encouraging results showed, at the early checkpoint of 7 days
after injection, the absence of toxicity of PEGylated small-
sized gold nanoparticle in liver spleen, kidney, heart and lung
[1].
In the field of cancer, the possibility to link antibodies to
nanoshells using PEG enables the use of these biocompatible
nanoshells for the delivery of drugs to targeted tumor cells.
The goal of such innovative treatment is double to enhance the
drug effect on targeted tumor cells and to reduce the toxic
effect of the anticancer drug on normal organs. A prerequisite
for the use of these biocompatible nanoparticles in oncology
daily practice is to check in vivo their tolerance in the long-
term and on the organs that are the most sensitive to efficient
anticancer drugs, particularly the liver, bone marrow, kidney,
heart and lung [7, 8].
To perform this study, we used human tumor xenografts in
immunodeficient mice. This in vivo model enables sequential
analyses in the different physiological compartments represented
by blood, normal and tumoral tissues [9], [10]. In this preclinical
model, we studied human renal cancer, since this highly
vascularised cancer frequently develops haematogenous
metastases and resists to anticancer drugs at non-toxic
therapeutic doses [11]. We performed a sequential analysis of
uptake and distribution of large-sized PEGylated gold nanoshells
and focussed the study on their intracellular distribution in the
xenografted human cancers, as well as on their long-term
tolerance in normal mouse organs.
Experimental section
Nanoparticle characteristics
Gold nanoshells composed of a ~20-nm Au shell around
a ~130-nm silica core and PEGylated (MW=5,000) were
purchased from Nanospectra Biosciences (Houston, TX,
USA). The nanoparticles were characterised using transmission
electron microscopy (TEM) and the absorbance spectrum was
evaluated with a Genesys 10S UV-VIS spectrophotometer
(Thermo Scientifique, France).
Dynamic light scattering (DLS) and zeta potential
measurements were carried out with a Nanosizer ZS90
instrument (MALVERN) at 25 °C. Hydrodynamic diameters
were obtained using the cumulant method.
PEG density is estimated at ~10–15 pmol/cm2 (about 13,
000 molecules/particle) (Nanospectra Biosciences, TX,
USA).
Human renal cancers and mice
For the xenografts, human renal cancer cell carcinoma
samples were taken from surgical pieces for Tumorothèque
of Hopital Saint Louis by pathologists, after the tumoral tissue
necessary to establish the diagnostic had been taken. Informed
consent for the use of the tumor sample for research was
obtained for each patient. The study was approved by the
University Board Ethics Committee and conducted in
accordance with the Declaration of Helsinki.
The animal study was approved by the Ethics Committee
for animal experimental studies of the University Institute
board. NMRI/nude 7-week-old female mice purchased from
Janvier (R. Janvier, France) were maintained in specific
pathogen-free animal housing.
Ten cubic millimeters of human renal cancer were
grafted subcutaneously on mice, under xylasin (10 mg/kg
body weight) and ketamin (100 mg/kg body weight)
anaesthesia. The follow-up was performed daily and
included a clinical score and assessment of tumor growth.
Xenografted tumors were measured in two perpendicular
diameters with a calliper every day and calculated as V =
L ×l2/2, L being the largest diameter (length), l the smallest
(width) [12]. Daily, mice were weighed and assessed for
behavioural changes and all data were recorded using the
FileMakerPro software.
Pharmacokinetics in mice
At different time points and on different organs, we quantified
the amount of gold and also assessed a possible toxicity in
nude mice and in mice xenografted with human renal cancer.
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Gold nanoshells administration
In normal nude mice, gold nanoshells were intravenously
injected with 100 μL NPs (3×109 NP/mL) (n =5) or with
PBS as control (n =3). In nude mice, xenografted with human
renal cancer gold nanoshells were intravenously injected with
100 μL NPs (3×109 NP/mL) (n =5) or with PBS as controls
(n =3). After injection, mice were weighed and assessed daily
for behavioural changes and all data were registered using the
FileMakerPro software.
Sequential blood and tissue sampling
For all mice, the whole blood, heart, kidney, lung, liver,
spleen, ovary, adrenal gland, lymph node and brain were
systematically sampled. For xenografted mice, a sample from
the tumor was also taken. The time points for sampling for
normal nude mice were 1, 7 and 15 days and 1, 2, 3 and
6 months. The time points for sampling for xenografted nude
mice were 5 and 30 min, 2 and 6 h and 1, 7 and 15 days to
respect the ethic rules regarding maximal tumor growth. All
tissue samples were cut into three parts: one part was snap-
frozen for inductively coupled plasma mass spectrometry
(ICP-MS) analysis, another part was glutaraldehyde-fixed
for electron microscopy and a third was formalin-fixed and
paraffin-embedded for dark field microscopy analysis and
histological analysis.
Spectrometric analyses in blood and tissue samples
To quantify the gold content in blood and tissue samples at the
different time points described above, ICP-MS was
performed. Fresh samples were weighed. After drying at
80 °C overnight, they were weighed again and digested in
nitric acid/HCl (Sigma). Remaining minerals were analysed
using ICP-MS (Elan DRCe, Perkin Elmer, Les Ulis, France).
Samples were nebulized in an argon plasma (6000–8000 °C).
The ions formed by nebulization were extracted from the
plasma, introduced into a mass spectrometer and separated
according to their mass on charge ratio (m/z). Gold content
was measured at mass 197, a level at which no interference
occurs. The detection limit was 1 ng/L.
Gold nanoshell distribution and assessment of toxicity
in the different mouse organs
In the different tissue samples systematically taken during
autopsies of mice performed at different time points from
1 day to 6 months, histological analyses were performed on
hematoxilin eosin staining to assess whether tissue damages
linked to toxicity could be detected. In the organs from mice
euthanised early (between 1 and 15 days), particular attention
was paid to the following features: acute hepatotoxicity with
hepatocyte necrosis and inflammatory infiltrate in the portal
areas; hypoplasia or complete aplasia of the bone marrow;
acute nephrotoxicity with endothelial damage, fibrin deposit
in the glomerular areas and necrosis of epithelial tubular cells;
cardiotoxicity with endocardial damage. In the organs from
mice euthanised at late time points (1, 2, 3 and 6 months),
particular attention was paid to the following features of long-
term toxicity: fibrosis and inflammatory infiltrate in the liver;
glomerular sclerosis and interstitial fibrosis with inflammatory
infiltrate in the kidney; diffuse interstitial fibrosis and
inflammatory infiltrate in the lung; and possible bone marrow
fibrosis or brain damage.
Assessement of gold nanoshell distribution in xenografted
human renal cancer
The distribution of gold nanoshells in xenografted human
renal cancer was assessed using dark field microscopy and
TEM to analyse the different types of cells within the tumor.
Dark- field microscopy
Five-micromillimeter-thick tissue sections from xenografted
human renal cancer were studied using a microscope
(Olympus AX, Tokyo, Japan) equipped for both bright field
and dark field microscopy. Using bright field, we could focus
our analyses on tumoral cells and avoid areas of necrosis.
Using dark field on the tumor area identified with bright field
microscopy, we could assess the distribution and the relative
density of the nanoparticles. Images were captured at ×40
magnification, on the same tumor areas successively analysed
using bright field and dark field microscopy.
Transmission electron microscopy
After fixation in 2 % glutaraldehyde in caccodylate buffer, the
samples of human renal cancers were embedded in Epon
resin. Ultrathin sections were observed using a Hitachi HF-
2000 transmission electron microscope (Hitachi, Tokyo,
Japan). TEM analyses focussed on the presence of gold
nanoshells in the different types of cells observed in the
human renal cell cancer: tumoral epithelial cells, vascular
endothelial, smooth muscle and pericyte cells, cells from the
inflammatory infiltrate including macrophages, and
fibroblasts and fibrocytes from the conjunctive stroma.
Statistics
All data were expressed asmean results ± SEM (standard error
of mean). The paired Student’s t test was used for statistical
analysis. A p value of less than 0.05 was taken to indicate
statistical significance.
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Results and discussion
We studied here in vivo uptake and cellular distribution of
gold nanoshells in a preclinical model of xenografted human
renal cancer.
For this study, we chose gold-silica nanoshells with a size
between 130 and 150 nmbecause (i) these large nanoshells are
suitable for imaging and hyperthermia in vivo [13] and (ii)
gold is well tolerated and does not induce toxicity in human
beings after intravenous or intra-articular injection [14].
We studied gold–silica nanoshells coated with PEG
because PEG polymers form a hydrophilic layer and sterically
block the electrostatic or hydrophobic interactions with
opsonins [15]. These plasma proteins are less adsorbed on
nanoshell surfaces, reducing their aggregation and their
clearance by phagocytic cells. At a temperature of 25 °C, the
zeta potential of the solution of PEGylated nanoshells used in
our study was −25 mV for pH 5.6. The dynamic light
scattering of gold nanoshells showed a good dispersion of
gold nanoshells (supplementary Fig. S1A). The
hydrodynamic size of PEGylated gold nanoshells in water
was 185 nm (PDI 0.104). This was concordant with the result
obtained in transmission electron microscopy (supplementary
Fig. S1B). To determine the optimal dose of nanoshell to be
injected in mice, we performed in vitro cytotoxicity test
(MTT) using three types of cell lines, one normal human
endothelial cell line (HUVEC) and two human cancer cell
lines (CAKI 1, 786-0). We checked these cells lines for 24 h
using different concentrations of gold nanoshells: 1.5×109
NP/mL, 3×109 NP/mL, 15×109 NP/mL, 3×1010 NP/mL.
The concentration of 3×1010 NP/mL induced toxicity on the
three cell lines, the concentration of 15×109 NP/mL induced
toxicity on the tumor cell but not on the endothelial cell line.
The concentration of 3×109 NP/mL was the highest
concentration that did not induce any sign of toxicity on any
of the three cell lines tested. This dose is in the range of doses
previously tested by other teams, i.e between 10 μg/kg [16]
and 8,000 μg/kg [17]. These previous studies focussed on
early cytotoxic effect while we analysed in vivo both early
and late toxic effects in our preclinical model. The late effect
was assessed 6 months after injection because 6 months is a
time point commonly used in clinics to assess chronic toxicity.
We analysed the uptake of these nanoshells from blood flow
using ICP-MS because it is a sensitive method that enables
detection of small quantities of gold [18]. As expected, we
observed a decrease fromDay 1 (381±111 ng/g) to Day 180 (1
±1 ng/g), a time point when quantities of gold were nearly
undetectable (Table 1). The uptake of gold spherical
nanoparticles of 100, 200 and 250 nm, has been studied after
intravenous injection inmice [19] and in rats [20]. The quantity
of gold detected in blood by ICP-MS 24 h after injection was
higher for 100-nm than for 250-nm gold nanoparticles in the
experiments performed in rats [20] (Table 2), whereas no gold
was detected in blood in the experiments performed in mice
receiving 100-nm nanoparticles[19].
We systematically studied the biodistribution of PEGylated
gold–silica nanoshells in organs of nude mice at different time
points: Day 1, 15, 30, 60, 90 and 180. Using ICP-MS, we
found a large amount of gold in the liver and spleen 24 h after
injection (9,738±816 ng/g and 9,200±730 ng/g, respectively;
Table 1). In the liver, the peak accumulation was observed at
Day 30 (35,872±2,492 ng/g) with a significantly lower level
when compared to Day 180 (3,723±376 ng/g) (p <0.005). In
the spleen, we also found a large amount of gold at Day 1 (9,
200±730 ng/g). However, in the spleen the ICP-MS
performed at different time points showed a progressive
accumulation with a significant higher level when gold
quantities at Day 1 (9,200±739 ng/g) were compared to gold
quantities at Day 180 (33,857±2,564 ng/g) (p <0.005). Dark
field analyses performed on liver and spleen tissue sections at
3 and 6 months after nanoparticle injections showed a large
accumulation of gold nanoparticles in the two organs.
Table 1 Gold quantification in organs of normal non-xenografted nude mouse (ng/g of tissue) from Day 1 to Day 180
Tissues Day 1 Day 15 Day 30 Day 60 Day 90 Day 180
Blood 381 (±111) 197 (±50) 147 (47) 99 (±28) 43 (±12) 1 (±1)
Liver 9,738 (±816) 16,615 (±800) 35,872 (±2,492) 16,601 (±765) 8,187 (±534) 3,723 (±376)
Bone marrow 13 (±8) 70 (±23) 57 (±13) 20 (±5) 19 (±9) 19 (±5)
Spleen 9,200 (±730) 13,511 (±2,360) 19,398 (±635) 21,406 (±1,956) 27,654 (±300) 33,857 (±2,564)
Kidney 395 (±19) 309 (±34) 161 (±45) 126 (±36) 29 (±15) 61 (±20)
Lung 55 (±21) 43 (±13) 54 (±12) 15 (±12) 21 (±12) 17 (±12)
Adrenal gland 306 (±12) 76 (±20) 53 (±15) 56 (19) 21 (±6) 47 (±6)
Lymph node 135 (±27) 239 (±73) 208 (±77) 255 (±75) 146 (±66) 120 (±25)
Ovary 46 (±14) 32 (±13) 12 (±6) 15 (±6) 10 (±8) 32 (±27)
Heart 14 (±5) 17 (±7) 13 (±5) 18 (±6) 15 (±7) 8 (±3)
Brain 12 (±4) 5 (±5) 1 (±1) 11 (±2) 5 (±3) 7 (±4)
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Comparison of the density of the nanoparticles at the two time
points showed an increase in the spleen and a decrease in the
liver, thus confirming the results obtained with ICP-MS
(Fig. 1). The large accumulation of gold nanoparticles in the
liver and spleen, also observed in mice for different size of
spherical gold nanoparticles [20], could be linked to the fact
that the capillaries in the spleen and liver are discontinuous [2]
and lined by cells with phagocytic capacity. Phagocytic cells,
particularly macrophages, are more numerous in the spleen
than in the liver [21] and this fact could explain the
discrepancy between the progressive diminution of gold
nanoparticles in the liver and the progressive accumulation
in the spleen. In addition, experimental data onmouse Kupffer
cells, i.e. liver phagocytic cells, following intravenous
injection of bacteriophage [22] demonstrated that after initial
phagocytosis, there was an immediate and rapid decrease in
the number of plaque-forming units (PFU) which could be
recovered from both liver and spleen; however, as soon as
3 days after injection, the number of PFU which could be
recovered from the spleen was greater than that found in the
liver. At Day 5, there was as many as 50 times more PFU in
the spleen than in the liver. In the present study, we assessed a
concentration of gold nanoparticles ten times greater in the
spleen than in the liver 6 months after injection.
We performed systematic pathological analyses to assess
signs of toxicity at the different time points when the different
organs of nude mice were analysed: Days 1, 15, 30, 60 and
180. We did not detect any signs of acute toxicity such as
hypoplasia or complete aplasia of the bone marrow; acute
nephrotoxicity with endothelial damage, fibrin deposit in the
glomerular areas and necrosis of epithelial tubular cells; or
cardiotoxicity with endocardial damage.
Regarding long-term toxicity, the greatest concentration of
PEGylated gold silica nanoshells was found in the liver and
spleen. Therefore, after dark field analysis, the same tissue
sections from the liver and spleen 3 and 6 months after gold
nanoshell injection were analysed using bright field
microscopy to detect signs of toxicity. As shown in Fig. 1,
no necrotic cell, no fibrosis and no inflammatory infiltrate
were found. This is in accordance with the absence of any
abnormalities in the clinical score used for the mouse follow-
up. No similar study on long-term organ toxicity has been
performed, as far as we know, in preclinical models.
In our study, we injected intravenously a single dose of
160 μg/kg gold nanoshells and we did not observe any toxicity
either at early or long term. In three other studies using
intravenous injection of gold nanoshells with a diameter larger
than 100 nm, no toxicity was observed [13, 14], even in cases of
repeated injections [3]. An early toxic effect on the liver and the
lung was observed in only one mouse series, for gold particles
of 8 to 37 nm of diameter injected intraperitoneally. As far as we
know, only one previously published study focussed on long-
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the dose injected (1,400 vs 160 μg/kg) and the size of the
nanoparticles (40 nm vs 150 nm) but no long-term toxicity
was found, as in our study.
Apart from the liver and spleen, in the other organs
analysed at different time points in normal nude mice, results
of ICP-MS are also confirmed by dark field analyses, but the
quantities of gold were much smaller than in the liver and
spleen. The kidney is the organ where we detected the less low
quantity of gold, with a decrease between Day 1 (395±19 ng/
g) and Day 180 (61±20 ng/g). These data show that gold
nanoparticles moved to the kidney, as expected, since the
kidney physiological function is filtering the entire blood flow
through the fenestrated endothelium of glomerular capillaries
[23]. However, the urinary excretion was low and this was
probably linked to the 5.5-nm size of the capillary
endothelium pores [18, 24], far smaller than the 150-nm
diameter of the gold silica nanoshells we had injected.
Fig. 2 Uptake of gold particles. Data obtained at early time points in
nude mouse xenografted with human renal cancer. a Induced coupled
plasma-mass spectrometry (ICP-MS) for gold quantification (logarithmic
representation) in the blood, liver, spleen, bonemarrow, kidney and tumor
at 5 and 30 min, 2 and 6 h and Day 1, 7 and 15. A significant decrease is
observed in the blood, bone marrow and tumor when gold quantities are
compared at 5 and 30 min, reflecting the rapid uptake of gold particles in
highly vascularized areas, whereas an increase is observed in the liver and
spleen when gold quantities are compared at 5 min and 15 days, reflecting
the progressive uptake and stock of gold nanoparticles in these organs
rich in phagocytic cells. b Distribution of gold nanoparticles in the
xenografted human renal cancer at the same early time points. Dark
field analysis shows a preferential distribution of gold nanoparticles in
capillary wall areas at 2 h and in tumor cells at Day 1. Transmission
electron microscopy shows an uptake of gold nanoparticles by
endothelial cells at 6 h with a distribution in both endothelial and
tumoral cells at Day 1, followed by an uptake and stock in phagocytic





















Fig. 1 Long-term toxicity study. Data obtained at late time points in
normal non-xenografted nude mouse. Systematic histological analysis
(H&E staining), 3 and 6 months after injection, in the spleen, liver, bone
marrow and lung, did not show any tissue damage linked to toxicity, such
as necrosis, fibrin deposit in vascular areas, inflammatory infiltrate,
fibrosis or bone marrow hypoplasia or aplasia. Dark field microscopy
analysis on the same areas, at the same time points, shows a high intensity
signal in the liver and spleen at 3 months followed at 6 months by a
decrease in the liver and an increase in the spleen. A very weak signal is
detected in the kidney at 3 and 6 months and no signal is observed in the
bone marrow and lung at the same time points. Magnification ×400






















































































bone marrow kidney tumor
5 min 30 min 120 min 360 min 1 Day 7 Days 15 Days
2 hours Day 1









Gold Bull (2013) 46:257–265 263
In the bone marrow (13±8 ng/g), lung (55±21 ng/g),
adrenal gland (306±12 ng/g), lymph node (135±27 ng/g)
and ovary (46 ±14 ng/g), very small gold quantities were
detected at Day 1 and these quantities decreased over time
(Table 1). In the brain, only traces of gold were found. This is
in accordance with the clinical follow-up over 6 months since
the mice did not show any behavioural abnormality, weight
loss or mortality.
Regarding toxicity in the different organs studied, apart
from the liver and spleen, pathological analyses of tissue
sections of different time points did not show any signs of
thrombosis, fibrin deposits or inflammatory infiltrate in the
glomeruli at early time points and no glomerular sclerosis,
interstitial fibrosis or inflammatory infiltrate in the kidney at
late time points. There was no sign of hypoplasia or complete
aplasia of the bone marrow. No interstitial fibrosis or
inflammatory infiltrate was detected in the lung or heart,
whether at early or late time points (Fig. 1). These data,
provided by our preclinical model, are important because the
treatment of cancer associating radiotherapy and poly-
chemotherapy can induce vascular and interstitial damages
in the kidney and heart [25], and life-threatening damages
such as diffuse pulmonary fibrosis, and bone marrow aplasia.
These severe complications linked to radiotherapy and poly-
chemotherapy are systematically sought during follow-up of
cancer patients under treatment and it is important to
demonstrate that the uptake and the accumulation of large
spherical gold silica nanoshells do not, on its own, induce
any systemic organ damage.
This absence of toxicity, at early and late time points, on the
organs most sensitive to efficient anticancer drugs enables
further applications of gold nanoshells for local delivery of
drugs on cells targeted through specific antibodies [26].
The study on xenografted mice was focussed on the tumor
xenograft, but we also systematically studied the organs at
different time points: 5 and 30 min, 2 and 6 h and 1, 7, 15 days
(Fig. 2a).
When we compared the gold quantities detected by ICP-MS
and gold nanoshell distribution in tissues using dark field
analysis, we did not find any significant difference in the
different organs of normal nude mice and of the xenografted
nudemice. This implies that the engraftment of the human renal
cancer did not change significantly the systemic distribution of
large gold nanoshells after intravenous injection.
Regarding the xenografted human renal cancer, we
successively studied the uptake of gold nanoshells from the
blood and their distribution in the different cellular components
of the tumor: tumor cells, microvessels, phagocytic interstitial
cells.
When we compared the gold quantities in blood and
xenograft at different time points, we found that in the two types
of samples the larger amounts were found at the first time points
(5 min), with a decrease at the successive time points, and
significantly smaller gold quantities at Day 15 compared to the
5-min time point. These kinetic particularities were not found in
the liver, spleen, bone marrow or kidney (Fig. 2a). These kinetic
data in the blood and xenografted tumor could be linked to the
fact that human renal cancer is a highly vascularised malignant
tumor [11], and that the microvessels of malignant tumors are
dystrophic with possible absence of pericytes, irregular thickness
or absence of continuity of basementmembrane [27]. In addition,
experimental data in mice have demonstrated that gold
nanoparticles are able to pass through large gaps in endothelial
cells and accumulate into interstitial spaces [3]. This
phenomenon is known as the enhanced permeability and
retention effect (EPR effect) [28].
To precisely determine the distribution of large gold
nanoshells in the different cellular components of the
human renal cancer, we used two imaging methods: dark
field and TEM.
Gold nanoshells could be detected in tumor sections using
dark field microscopy as early as 5 min after injection. They
remained located within the microvessels as long as 2 h
(Fig. 2b). There was a striking distribution change between
Day 1 and Day 15, with a distribution within cytoplasm of
cells located outside the microvessel network. Transmission
electron microscopy confirmed these results and enabled a
more precise analysis at higher magnification. As early as 6 h
after injection, gold nanoshells, easily detected because they
are electron dense with a regular round shape and a constant
diameter, were found in the sub-endothelial compartment,
thus showing they had crossed over the microvessel
endothelial wall. At Day 1, gold nanoshells could be detected
both in the cytoplasm of microvessel endothelial cells and in
the cytoplasm of tumor cells. After Day 7, gold nanoshells
were mainly found within the cytoplasm of macrophages,
easily identified because of their phagolysosomes. Rare
nanoshells were detected into the cytoplasm of tumor cells at
Day 15 (supplementary Fig. 2).
This original sequence not previously reported, using TEM
to identify the different cell components of human renal
cancer, opens new fields for medical applications using large
PEGylated gold nanoshells by optimising the time for targeted
hyperthermia or local drug delivery to tumor cells.
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